sulfonylureas (SUs)

Case 5: Graduate Student with Atypical Symptoms

Tags: beta cell pathophysiology, DPP-4 inhibitors, GLP-1 agonists, glycemic control, insulin therapy, sulfonylureas (SUs), thiazolidinediones (TZDs)

A 25-year-old graduate student originally presented to you with symptoms of a UTI. An urinanalysis showed signs of infection, as well as glycosuria.

Continue Reading

Tailoring Clinical Practice Guidelines for Patients with Type 2 Diabetes

Posted September 21, 2011 by Sonal Singh, MD, MPH

Tags: DPP-4 inhibitors, metformin, sulfonylureas (SUs), thiazolidinediones (TZDs)

Several guidelines emphasize the need to use existing therapeutic options to help patients and providers achieve various treatment goals, including target glycated hemoglobin levels to improve microvascular outcomes among patients with type 2 diabetes.

Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations.

Bennett, Wendy L; Maruthur, Nisa M; Singh, Sonal; Segal, Jodi B; Wilson, Lisa M; Chatterjee, Ranee; Marinopoulos, Spyridon S; Puhan, Milo A; Ranasinghe, Padmini; Block, Lauren; Nicholson, Wanda K; Hutfless, Susan; Bass, Eric B; Bolen, Shari

Annals of internal medicine; 2011 May 3;154(9):602-13. PMID: 21403054;

Category: Interventions;

Tags: DPP-4 inhibitors, GLP-1 agonists, glycemic control, metformin, sulfonylureas (SUs), thiazolidinediones (TZDs)

Effect of antihyperglycemic agents added to metformin and a sulfonylurea on glycemic control and weight gain in type 2 diabetes: a network meta-analysis.

Gross, Jorge L; Kramer, Caroline K; Leitão, Cristiane B; Hawkins, Neil; Viana, Luciana V; Schaan, Beatriz D; Pinto, Lana C; Rodrigues, Ticiana C; Azevedo, Mirela J

Annals of internal medicine; 2011 May 17;154(10):672-9. PMID: 21576535;

Category: Interventions / Metformin;

Tags: glycemic control, metformin, sulfonylureas (SUs), weight

T2DM and Fatty Liver Disease: Is What’s Good for the Gander Good for the Goose?

Posted April 7, 2011 by Kim C. Dixon, MD

Tags: DPP-4 inhibitors, GLP-1 agonists, glycemic control, lifestyle changes, metformin, sulfonylureas (SUs), thiazolidinediones (TZDs), weight

Fatty liver disease is the most common cause of chronic liver disease in North America[1] and is becoming one of the top reasons for liver transplantation. Fatty liver causes inflammation that can lead to fibrosis, cirrhosis, and hepatocellular carcinoma.

Do Beta Cells Need Secretory Respite?

Posted October 15, 2010 by Christopher J. Rhodes, PhD

Tags: beta cell pathophysiology, GLP-1 agonists, glycemic control, insulin therapy, lifestyle changes, metformin, sulfonylureas (SUs), thiazolidinediones (TZDs), weight

Evidence that protecting pancreatic beta cells from chronic overstimulation to maintain glucose homeostasis has led to the concept of “beta cell rest” to preserve or restore beta cell function by temporarily inhibiting insulin secretion.

Primary Care View on Case 2: Failing Metformin

Posted September 7, 2010 by Doron Schneider, MD, FACP

Tags: GLP-1 agonists, glycemic control, lifestyle changes, metformin, sulfonylureas (SUs), thiazolidinediones (TZDs)

Case 2: Metformin Fails in T2DM Patient represents a clinical dilemma faced by every primary care doctor.

Betacell

A resource for physicians established by the Endocrine Society

Text Size:

About Topics